A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or…
Myeloma
GlaxoSmithKline’s investigational therapy belantamab mafodotin has been recommended for approval in the European Union, by the Committee for Medicinal Products for Human…
A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from…
A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or…
An office of the U.S. Food and Drug Administration (FDA) has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for…
A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with…
When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses…
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan…
Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 is affecting life…
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing…
